anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Psychogenic nonepileptic seizures (PNES) are a common type of functional neurological disorder in which patients experience seizurelike episodes. Health disparities based on race and socioeconomics, documented in children with epilepsy and adults with PNES, have not been reported in children and adolescents with PNES. We hypothesize that disparities exist in this population, which impact overall care and therefore influence outcomes.
METHODS: We retrospectively analyzed youth referred to our multidisciplinary clinic from 2018 to 2020. All patient charts were screened by social work before the visit to identify potential barriers to care, and a nurse conducted follow-up calls. Patients' race was identified from the electronic health record and compared with several variables. Outcomes were collected via phone follow-up. Descriptive statistics were produced, and comparisons between white patients and patients of other races were completed using Fisher exact tests and multivariable logistic regressions.
RESULTS: During the study period, 237 patients were eligible for the analysis. Sixty-eight patients (29%) identified as a race other than white. Only 60%, 56%, and 40% of the cohort were reached for follow-up at one, three, and 12 months, respectively. In general, outcomes were similar between racial groups; however, we found that patients of nonwhite race were more likely to receive support from social work due to barriers identified in screening (P = 0.045).
CONCLUSIONS: Health disparities based on race may exist in youth with PNES. A multidisciplinary clinic including social work may help mitigate barriers leading to more equitable care and similar outcomes for white and nonwhite youth with PNES.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in Table 1 are derived from 3 placebo-controlled trials that included 1,833 patients treated with LEQVIO, including 1,682 exposed for 18 months (median treatment duration of 77 weeks) [see Clinical Studies (14)]. The mean age of the population was 64 years, 32% of the population were women, 92% were White, 6% were Black or African American, 1% were Asian, and < 1% were other races; 6% identified as Hispanic or Latino ethnicity. At baseline, 12% of patients had a diagnosis of HeFH and 85% had clinical atherosclerotic cardiovascular disease (ASCVD).

Adverse reactions reported in at least 3% of LEQVIO-treated patients, and more frequently than in placebo-treated patients, are shown in Table 1.

Adverse reactions led to discontinuation of treatment in 2.5% of patients treated with LEQVIO and 1.9% of patients treated with placebo. The most common adverse reactions leading to treatment discontinuation in patients treated with LEQVIO were injection site reactions (0.2% versus 0% for LEQVIO and placebo, respectively).
OBJECTIVE: The management and surveillance of glandular pre-cancerous lesions of the uterine cervix present distinct challenges compared with squamous lesions, primarily attributed to the lower effectiveness of diagnostic methods such as cytology or colposcopy. This study aimed to investigate the long-term safety of fertility-sparing treatment for adenocarcinoma in situ and microinvasive adenocarcinoma of the cervix, while identifying factors associated with recurrence, with a particular emphasis on the role of human papillomavirus (HPV) testing.
METHODS: We retrospectively reviewed data from all patients with histopathologically confirmed adenocarcinoma in situ or microinvasive cervical adenocarcinoma who received treatment at a single center between 2002 and 2023. The study involved the examination of consecutive surgical specimens and the follow-up details. Factors associated with recurrence were assessed in a subgroup of patients with available long-term follow-up data (at least 6 months).
RESULTS: In total, 143 patients (112 with adenocarcinoma in situ and 31 with adenocarcinoma) were included in the analysis. Among the 86 patients who underwent fertility-sparing treatment, the recurrence rate was 9% (12% for adenocarcinoma in situ and 4% for adenocarcinoma) during a median follow-up period of 56.6 months (range 7-179). No patients who were HPV negative experienced recurrence during the follow-up period. In contrast, among patients who were HPV positive, the recurrence rate was 38%. Additionally, HPV 16/18 positivity displayed a notable association with a higher risk of recurrence compared with the other high-risk genotypes, although this difference did not reach statistical significance (83% vs 10%; p=0.083, log-rank).
CONCLUSION: Our retrospective study demonstrated a significant association between the risk of recurrence and HPV status during the follow-up period. Consequently, long-term follow-up utilizing HPV testing and genotyping appears to be a secure alternative to a hysterectomy.
BACKGROUND: Pediatric migraine prophylaxis is indicated when headaches are frequent and/or disabling. We aimed to conduct a study to compare the efficacy of cinnarizine and amitriptyline in pediatric migraine prophylaxis.
METHODS: In a randomized, double-blind trial, patients aged 4-17 years with migraine who were eligible for prophylaxis enrolled. The primary outcome was a reduction response rate of ≥50% with p < 0.005 with respect to headache characteristics. The secondary outcome was migraine disability assessment. We evaluated patients every four weeks for three months: T1: week 4, T2: week 8 and T3: week 12. The safety profile was also assessed.
RESULTS: Thirty patients were randomly assigned to each group. However, 43 patients completed the trial. Headache frequency decreased in amitriptyline group more effectively in T1 (p = 0.004). Amitriptyline was more successful in reducing the headache duration in all three periods (p < 0.005). There was no significant difference in severity improvement and reducing disability score between the two groups (p > 0.005). No serious adverse events were observed.
CONCLUSIONS: Both medications are effective in ameliorating migraine headaches and related disabilities. However, amitriptyline appears be a preferable option over cinnarizine, given its faster onset of action, efficacy in reducing headache duration and longer-lasting effects.Trial Registration: The study was registered with the Iranian Registry of Clinical Trials (IRCT) under the code IRCT-20191112045413N1.
The VALIANCE Study is a 15,000 patient, multicentre, prospective observational cohort of adults undergoing elective same-day noncardiac surgery and who will be followed for 90 days after surgery. The primary objective of the study is to determine the incidence of major cardiovascular complications after same-day surgery. Patients will also be followed for the occurence of other adverse postoperative complications and determine their change in quality of life at 90 days after surgery. VALIANCE will inform on the risk factors for postoperative complications and allow to develop risk prediction tools to guide patient selection and risk stratification of patients undergoing same-day surgery. The study will also look at validating the use of the Duke Activity Status Index questionnaire, Clinical Frailty Scale, and the Revised Cardiac Risk Index. Postoperative pain will be evaluated using the Brief pain inventory score and quality of life using the EQ-5D-5L questionnaire.
Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Severe influenza is associated with defects in pulmonary innate immunity, a phenomenon leading to secondary bacterial infections. The gut microbiota can control immune/inflammatory responses locally and at distant sites. The inventors hypothesized that perturbation of the gut microbiota during severe influenza might participate in bacterial superinfection. Their data demonstrated that influenza infection profoundly altered the functionality of the gut microbiota as assessed by the altered production of short chain fatty acids (SCFAs). Remarkably, treatment of IAV-infected mice with acetate, the main SCFA found systematically, reinforced host defenses against  S. pneumoniae . Lastly, the inventors showed that pharmacological manipulation of the FFAR2 agonist TUG-1375 provides the same benefit as acetate in the treatment of bacterial superinfection post-influenza. The present invention thus relates to the use of synthetic free fatty acid receptor 2 (FFAR2) agonist for the treatment of bacterial superinfections post-viral infection (e.g. post-influenza).
Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
Atopic skin is dry and itchy and lacks integrity. Impaired skin barrier results from altered lipid composition of the skin. A crucial skin lipid, cholesterol, provides flexibility and homeostasis of the cell membranes' lipid bilayer. Cholesterol-based creams and natural oils, especially blackcurrant seed oil, are beneficial for skin care as they hydrate the skin and improve its integrity. The major atopic symptom, skin dryness, can be overcome by the application of porous patches enhanced with cholesterol and natural oil. The base of the patches is constructed of polyimide (PI) nanofibers with cholesterol coatings and externally added blackcurrant seed oil. The presence of cholesterol in PI mats hinders the passage of oil through the patches to the skin, resulting in sustained and prolonged skin hydration. The theoretical and numerical investigations of oil dynamics in porous mats confirmed the experimental results, showing a prolonged skin hydration effect up to 6 h. Additionally, as demonstrated by in vivo tests on atopic mice, cholesterol patches lower serum immunoglobulin E levels and expression of proinflammatory cytokines in the skin, thereby accelerating skin healing. Our results hold great promise for the long-term application of the patches in atopic dermatitis treatment.
PURPOSE:The titled food for adjusting the rhythm, consisting essentially of a plant extract saponin extracted from a specific plant, e.g. ginseng, Bupleurum root, etc., and capable of always adjusting the hormone intraday rhythm normal, and eliminating general malaise etc. by eating. CONSTITUTION:A food for adjusting the hormone intraday rhythm consisting essentially of a plant extract saponin extracted from ginseng, at least one of ginseng, Bupleurum root, watermelon, dishcloth gourd and Gynostemma pentaphyllum Makino. The above-mentioned food is capable of eliminating general malaise, e.g. stiffness in the shoulders, irritation, pollakiuria, etc. caused by imbalance in hormone secretion rhythm, and eatable for a long period without resistance. The above-mentioned saponin extract usually may be an optional form for taking in 20-1,000mg/day as powder.
PROBLEM TO BE SOLVED: To obtain an antiaging agent which keeps the skin taut and elastic and can maintain the skin in a fresh state. SOLUTION: This antiaging agent contains a solvent extract from a gromwell (botanical name: Lithospermum erythrorhizon Siebold et Zuccarini). The extract from the gromwell possesses elastase inhibitory effect and prevents skin from aging. The extract from the gromwell on this invention is blended in an amount of 0.0005-20.0 wt.%, preferably 0.001-10.0 wt.%, based on the whole weight of the preparation for external use in the dry basis. When it is less than 0.0005 wt.%, the effect on this invention is not efficiently exerted and when it is more than 20.0 wt.%, it is not favorable due to the difficulty of pharmaceutical manufacturing. Further, even when the amount of more than 10.0 wt.% is blended, the very great improvement of the effect is not observed.
Periodontitis, an inflammatory disease, can cause significant damage to the oral tissues which support the teeth. During the early development of periodontitis, periodontal ligament fibroblasts (PDLFs) undergo metabolic reprogramming regulated by hypoxia-inducible factor 1α (HIF-1α), which is strongly linked to the progression of inflammation. However, the precise mechanisms by which PDLFs regulate HIF-1α and its associated metabolic reprogramming during early inflammation remain unclear. This study illustrated that brief and low-dose exposure to Escherichia coli (E. coli) lipopolysaccharide (LPS) can serve as a non-hypoxic stimulus, effectively replicating early periodontal inflammatory reactions. This is evidenced by the upregulation of HIF-1α expression and the activation of HIF-1α-mediated crucial glycolytic enzymes, namely lactate dehydrogenase a, pyruvate kinase, and hexokinase 2, concomitant with an augmentation in the inflammatory response within PDLFs. We observed that the effects mentioned and their impact on macrophage polarization were notably attenuated when intracellular and extracellular stores of Ca2+ were depleted using BAPTA-AM and Ca2+-free medium, respectively. Mechanistically, our findings demonstrated that the transcriptional process of HIF-1α is regulated by Ca2+ during E. coli LPS stimulation, mediated through the signal transducer and activator of transcription 3 (STAT3) pathway. Additionally, we observed that the stabilization of intracellular HIF-1α proteins occurs via the endothelin (ET)-1-endothelin A receptor pathway, independent of hypoxia. Taken together, our research outcomes underscore the pivotal involvement of Ca2+ in the onset of early periodontitis by modulating HIF-1α and glycolysis, thereby presenting novel avenues for early therapeutic interventions.
ABSTRACT OF THE DISCLOSURE             Methods for diagnosing the onset or monitoring of the course of a disease comprising obtaining a T-cell nucleic acid or polypeptide test sample from an animal and detecting in such test sample a first target nucleic acid or polypeptide sequence correlated with the disease.   The first target nucleic acid or sequence corresponds to a DNA sequence encoding the variable region of a chain of a T-cell receptor.   The first target polypeptide sequence corresponds to a variable region of a chain of a T-cell antigen receptor.  Methods for treating an animal afflicted with a disease correlated with a T-cell clone containing a specific variable region.   The method comprises treating the animal with at least one antibody which is reactive with the specific variable region of the T-cell clone. Antibodies for detecting or treating a disease correlated with at least one T-cell clone containing a specific variable region wherein said antibody is specific for said variable region.
In order to evaluate whether electrical stimulation applied to the muscles within the forearm can evoke functional movement in the hand, participants will receive transcutaneous electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.

Participants will be asked to attend up to 4 study sessions a week for up to 8 weeks, with each session lasting up to 4 hours. At these sessions, electrical pulses will be sent to the forearm muscles through electrodes placed on the skin. These electrodes may also be accompanied with a gel or lotion to allow for a better connection of the electrodes to the skin. The precision, specificity, and extent of hand and finger movements will be visually assessed in real time and later reassessed on video recordings of the session. The study will also involve the placement of sensors on the hand and finger to measure the amount of grip strength and evoked forces. In order to monitor the health of participants, the study will assess blood pressure and heart rate before, during, and after the electrical stimulation. Upon completion of these study sessions, the individual's participation in the study is considered complete.
Lightly coloured, hard, oxygen contg. wax prods. are prepd. by oxidising the side chains of olefin polymers (I) by treating particulate or molten (I) at 20-200 deg.C with a sulphuric acid chromic acid soln. contg. 60-140 g/l CoO3 and 400-600 g/l H2SO4. The reactants are intensively mixed throughout the oxidation. The prod. is lightly coloured, hard, odourless and can be prepd. in high yields without crosslinking. The wax can be used in (shoe) polishes, coatings for fruit, paper, corrosion protection, textile coatings, adhesives, pigment concentrates, carbon paper coatings, cosmetic compsns., candles, lubricants for metal working separating agents for resins, water repelling agents, printing inks, casting compsns. and lacquer wetting agents. The wax films have high gloss. The waxes can also be further reacted e.g. esterified with alcohols, hydrolysed, or saponified with metal ions or amidated.
One of the early symptoms of chronic venous disease (CVD) is varicose veins (VV) of the lower limbs. There are many etiological environmental factors influencing the development of chronic venous insufficiency (CVI), although genetic factors and family history of the disease play a key role. All these factors induce changes in the hemodynamic in the venous system of the lower limbs leading to blood stasis, hypoxia, inflammation, oxidative stress, proteolytic activity of matrix metalloproteinases (MMPs), changes in microcirculation and, consequently, the remodeling of the venous wall. The aim of this review is to present current knowledge on CVD, including the pathophysiology and mechanisms related to vein wall remodeling. Particular emphasis has been placed on describing the role of inflammation and oxidative stress and the involvement of extracellular hemoglobin as pathogenetic factors of VV. Additionally, active substances used in the treatment of VV were discussed.
The present invention relates to a new function of chitobiose and its application in health-care food. The chitobiose is a degradation product of chitin, and is an oligosaccharide formed by connecting 2N-acetylglucosamines by glycosidic bonds. Animal experiments show that the chitobiose has obvious alpha-glucosidase inhibition activity, the IC50 of the chitobiose is 2.0mg/mL, the fasting blood sugar level of type II diabetic mice can be obviously reduced to 6.1mg/mL, the fasting blood sugar value of the chitobiose is obviously lower than that of a control acarbose group by 7.9mg/mL, and the fasting blood sugar value range of the control acarbose group is close to the upper limit of the fasting blood sugar value range of normal healthy mice. Second, chitobiose significantly reduces serum lipid levels and inhibits pancreatic lipid peroxidation levels compared to acarbose. In addition, chitobiose stabilizes the body weight of diabetic mice. The compounding of the chitobiose and the xylo-oligosaccharide also has obvious effect of reducing blood sugar. The chitobiose has good hypoglycemic effect, and can be used for developing safe and effective health-care food for preventing and improving type II diabetes.
Patients' safety can be compromised in the transition of care between healthcare sectors. Optimal information flow across healthcare sectors and individualized medication treatment tailored to each patient is key to prevent adverse events and optimize patient treatment. Particularly, the inclusion of the general practitioner is important in this process; it could become a challenge to keep medication changes if this communication link is missing. The framework for complex intervention allows flexibility and adaption in meeting patients' needs by implementing tailored, possibly complex interventions in different healthcare settings. To examine the effect of a Medication Coordinator, who facilitates medication reviews in close collaboration with patients using My Medication Plan. The primary outcome is the proportion of potentially inappropriate medications. Secondary outcomes include patient-reported outcomes i.e., quality of life and medication burden. Additional outcomes include the patient's individual Medication Risk Score, if the patients are readmitted, and if the patients have contacted the staff at the hospital unit after the hospital discharge.
PURPOSE:To provide skin-beautifying cosmetic containing zinc lactate, storable stably for a long period and capable of developing and imparting excellent skin-beautifying effect. CONSTITUTION:The objective cosmetic contains 0.05-30wt% zinc lactate. Zinc lactate is dissolved and diffused rapidly in sebum and impregnated easily into the skin, and consequently, it develops excellent skin-beautifying effect by moderately inhibiting the tyrosinase activity in the dermatic tissue. Zinc lactate is compounded to conventional skin cosmetic such as cream, milky lotion, lotion, powder, etc. There are three types of zinc lactate, i.e. L-type, D-type and DL- type all of which have excellent tyrosinase-inhibiting activity, with L-type zinc lactate having the highest activity.
The present invention is active thymic peptide 5 (TP-5) isomer and its pharmaceutical application, and belongs to the fields of organic chemistry and chemical medicine. Structurally, the active TP-5 isomer has TP-5 amino sequence of Arg-Lys-Asp-Val-Tyr with one or two amino acids substituted by corresponding beta-amino acids or gamma-amino acids. It is prepares through a conventional Fmoc solid peptide synthesizing process. Phamacodynamical experiment shows that the active TP-5 isomer possesses obvious immunological enhancement effect, antitumor effect and antioxidant effect. Extracorporeal activity and stability measurement shows that the active TP-5 isomer has activity not lower than that of TP-5, raised stability, longer half life and thus enhanced curative effect. The present invention provides theoretic base for the research on the activity mechanism of thymic peptide and the development of new medicine.